Early drug development – shortening timelines effectively

Early drug developers gather to discuss maximising drug investments, toxicology, safety and biomarkers.

This summit addresses the strategies and tools to fully optimise the early drug development trajectory in order to bring safe, effective and commercially viable drugs to market faster whilst achieving regulatory approval.

Key learning outcomes this year include:

• Maximising investments to reduce risk and costs in early drug development
• Successfully utilising predictive modelling throughout early drug development
• Identifying which biomarkers are profitable and worth investment
• Adapting development models to cater for specific populations
• Overcoming stringent regulatory barriers for fast-track early drug development

Call for Papers
If you would like to be involved as a speaker or help shape the programme, please contact:

Hannah Azizi
Producer
Email: hannah.azizi@wtgevents.com
Tel: +44 (0) 207 202 7586